Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Atypical presentation of atypical haemolytic uraemic syndrome.

Basak R, Wang X, Keane C, Woroniecki R.

BMJ Case Rep. 2018 Feb 11;2018. pii: bcr-2017-222560. doi: 10.1136/bcr-2017-222560.

PMID:
29440240
2.

Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.

Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M.

Nephrology (Carlton). 2016 Mar;21(3):261-5. doi: 10.1111/nep.12582.

PMID:
26818219
3.

Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.

Dedhia P, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG.

Transplant Proc. 2017 Jan - Feb;49(1):188-192. doi: 10.1016/j.transproceed.2016.11.008.

PMID:
28104134
4.

Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.

Okumi M, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776. Review.

PMID:
26988663
5.

Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.

Chua J, Paizis K, He SZ, Mount P.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:18-22. doi: 10.1111/nep.12935. Review.

PMID:
28176472
6.

Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

de Holanda MI, Pôrto LC, Wagner T, Christiani LF, Palma LMP.

Clin Rheumatol. 2017 Dec;36(12):2859-2867. doi: 10.1007/s10067-017-3823-2. Epub 2017 Sep 13. Review.

PMID:
28905254
7.

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.

Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship TH, Kavanagh D, Unsal A.

J Med Case Rep. 2015 Apr 29;9:92. doi: 10.1186/s13256-015-0575-y.

8.

Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.

Gately R, San A, Kurtkoti J, Parnham A.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:32-35. doi: 10.1111/nep.12938. Review.

PMID:
28176475
9.

Complement activation: an atypical presentation of an atypical syndrome.

Iardino A, Bunin V, Truong LD, Preti HA.

BMJ Case Rep. 2017 Oct 30;2017. pii: bcr-2017-221798. doi: 10.1136/bcr-2017-221798.

PMID:
29084740
10.
11.

Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection.

Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E.

BMJ Case Rep. 2017 Apr 26;2017. pii: bcr-2016-219065. doi: 10.1136/bcr-2016-219065.

12.

Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.

Choo SZ, Brown F.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:4-6. doi: 10.1111/nep.12931. Review.

PMID:
28176471
13.

Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome.

Sari F, Inci A, Karakus V, Yilmaz B, Sarikaya M, Olmaz R, Kurtoglu E.

Saudi J Kidney Dis Transpl. 2017 Mar-Apr;28(2):388-391. doi: 10.4103/1319-2442.202783.

14.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
15.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9. English, Spanish.

16.

An extremely rare splice site mutation in the gene encoding complement factor I in a patient with atypical hemolytic uremic syndrome.

Ipe TS, Lim J, Reyes MA, Ero M, Leveque C, Lewis B, Kain J.

J Clin Apher. 2017 Dec;32(6):584-588. doi: 10.1002/jca.21549. Epub 2017 Apr 28.

PMID:
28455885
17.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

18.

Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012.

Åkesson A, Blom AM, Klintman J, Zetterberg E.

Nephrology (Carlton). 2017 Jul;22(7):555-561. doi: 10.1111/nep.12818.

PMID:
27175932
19.

Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.

Grenda R, Jarmużek W, Rubik J, Prokurat S, Miklaszewska M, Drozdz D, Zachwieja K, Ardissino G, Hofer J.

Pediatr Transplant. 2015 Sep;19(6):E130-4. doi: 10.1111/petr.12537. Epub 2015 Jun 18.

PMID:
26087050
20.

Ocular involvement in atypical haemolytic uraemic syndrome.

Sampedro López A, Domínguez Moro B, Baltar Martin JM, Garcia Monteavaro C, Barbón García JJ.

Arch Soc Esp Oftalmol. 2017 Dec;92(12):594-597. doi: 10.1016/j.oftal.2017.02.007. Epub 2017 Mar 24. English, Spanish.

PMID:
28347544

Supplemental Content

Support Center